Savilla has kidney failure and as a result is on dialysis and is lacking enough hemoglobin as her kidneys don’t produce EPO. Twice a month 4000 units of EPO are administered. There are many hurdles to overcome on a daily bases with endstage renal failure and this series of videos is made to give the viewer more reality about this debilitating disease.
Erythropoietin (EPO): A hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow. EPO is a glycoprotein (a protein with a sugar attached to it). Human EPO has a molecular weight of 34,000.
The kidney cells that make EPO are specialized and are sensitive to low oxygen levels in the blood. These cells release EPO when the oxygen level is low in the kidney. EPO then stimulates the bone marrow to produce more red cells and thereby increase the oxygen-carrying capacity of the blood.
EPO is the prime regulator of red blood cell production. Its major functions are to promote the differentiation and development of red blood cells and to initiate the production of hemoglobin, the molecule within red cells that transports oxygen.
The EPO gene has been found on human chromosome 7 (in band 7q21). EPO is produced not only in the kidney but also, to a lesser extent, in the liver. Different DNA sequences flanking the EPO gene act to control kidney versus liver production of EPO.
The measurement of EPO in the blood is useful in the study of bone marrow disorders and kidney disease. Normal levels of EPO are 0 to 19 mU/ml (milliunits per milliliter). Elevated levels of EPO can be seen in polycythemia, a disorder in which there is an excess of red blood cells. Lower than normal levels of EPO are seen in chronic renal failure.
